multivesicular liposome (depofoam) in human diseases

Drug development is a key point in the research of new therapeutic treatments for increasing maximum drug loading and prolonged drug effect. encapsulation of drugs into multivesicular liposomes (depofoam) is a nanotechnology that allow delivery of the active constituent at a sufficient concentration during the entire treatment period. this guarantees the reduction of drug administration frequency, a very important factor in a prolonged treatment. currently, diverse depofoam drugs are approved for clinical use against neurological diseases and for post-surgical pain management while other are under development for reducing surgical bleeding and for postsurgical analgesia. also, on pre-clinical trials on cancer depofoam can improve bioavailability and stability of the drug molecules minimizing side effects by site-specific targeted delivery. in the current work, available literature on structure, preparation and pharmacokinetics of depofoam are reviewed. moreover, we investigated approved depofoam formulations and preclinical studies with this nanotechnology.